CDI Now In-Network with Blue Cross and Blue Shield of Illinois

SALEM, Mass. — Commonwealth Diagnostics International, Inc. (CDI), The Leader in Hydrogen and Methane Breath Testing®, is now in-network with Blue Cross and Blue Shield of Illinois (BCBSIL), the state’s largest health insurance company. This significant development is part of CDI’s ongoing efforts to enhance accessibility to its clinically validated non-invasive at-home breath tests for…

CDI Launches MyGI Gateway™: A Cutting-Edge Provider Portal for Enhanced Patient Care

MyGI Gateway will transform hydrogen and methane breath testing with streamlined kit registration, advanced patient engagement, and analytics throughout the diagnostic process. SALEM, Mass. – October 20, 2023 – Commonwealth Diagnostics International, Inc. (CDI), The Leader In Hydrogen and Methane Breath Testing®, is excited to announce the launch of MyGI Gateway™, a cutting-edge cloud-based provider…

CDI and My Total Health Announce Strategic Partnership with CliniOps

Collaboration will accelerate and streamline gastroenterology (GI) clinical trials with an end-to-end platform for patient recruitment, enrollment, and management   Salem, Mass. and Fremont, Calif. – October 20, 2022 – My Total Health Inc., in partnership with Commonwealth Diagnostics International, Inc. (CDI), announced today a strategic partnership with CliniOps in which the companies will collaborate…

Commonwealth Diagnostics International (CDI) Expands Access to Naturopathic & Integrative Medicine Community Through New Partnership with Rupa Health

Commonwealth Diagnostics International, Inc. (CDI), an innovative GI health company providing industry-leading diagnostic tests and tools to help physicians identify and diagnose common sources of digestive distress and functional gastrointestinal ailments, today announced expanded access to the naturopathic and integrative medicine community through a strategic partnership with Rupa Health, a digital health platform making it…

Commonwealth Diagnostics International (CDI) Named Among the Top Healthcare Technology Companies of 2022

Salem, Mass. – August 11, 2022 – Commonwealth Diagnostics International, Inc. (CDI), an innovative GI health company providing industry-leading diagnostic tests and tools to help physicians identify and diagnose common sources of digestive distress and functional gastrointestinal ailments, is proud to be recognized as one of the Top 100 Healthcare Technology Companies of 2022 by…

My Total Health Partners with the American College of Gastroenterology to Provide Scientific and Clinical Education to Patients Suffering from GI Symptoms

Collaboration will expand MyGiHealth’s Learning and Treatment Centers as well as provide greater access to providers across the full spectrum of gastroenterology Salem, Mass. (October 26, 2021) – My Total Health Inc., in strategic partnership with Commonwealth Diagnostics International, Inc. (CDI), announced it will expand education content available via its MyGiHealth application with a new…

Commonwealth Diagnostics International, Inc. Cofounders Honored Amongst Peers in Business and Healthcare

Salem, Mass. – June 29, 2021 – Commonwealth Diagnostics International, Inc. (CDI) is pleased to announce that two of its cofounders, Craig Strasnick and Gray W. Rifkin, were honored recently amongst their peers in both business and healthcare. Strasnick, CDI President and CEO, was named to the Forbes Next 1000 list of upstart entrepreneurs redefining…

Commonwealth Diagnostics International, Inc. (CDI) announces expanded industry and research partnerships in the United States and abroad

Salem, Mass. – May 21, 2021 – Over the past 10 years, Commonwealth Diagnostics International, Inc. (CDI) leadership team has worked closely with industry stakeholders to support the gastroenterology (GI) community. Today, CDI is pleased to announce it has expanded partnerships with several industry and research partners both in the United States and abroad, including…

IBSchek® Granted PLA Code from AMA; CDI to Now Accept Insurance, Providing More Patients At-Home Access

Maximum out-of-pocket cost for first clinically validated IBS blood test also to be reduced, making it the most affordable IBS diagnostic test on the market Salem, Mass. – February 3, 2021 – For too long millions of patients requiring a simple and reliable blood test for Irritable Bowel Syndrome (IBS) have been met with soaring…

CDI Introduces Validated At-Home Collection Kit for IBSchek®

The Improved Sample Collection Method Expands Access to the Blood Test for Diagnosing DiarrheaPredominant and Mixed-Type Irritable Bowel Syndrome SALEM, MA February 1, 2020 – Commonwealth Diagnostics International (CDI), Inc., an international diagnostic service provider specializing in functional gastrointestinal disorders, recently announced the commercial re-launch of IBSchek®, the first clinically validated biomarker blood test for…